Erin Hunter, Assistant Editor

Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.

Capivasertib combined with fulvestrant doubled progression-free survival in patients with recurrent or progressed advanced stage HR-positive HER2-negative breast cancer compared to placebo.

Golidocitinib (DZD4205) is the first Janus kinase 1 inhibitor to be used for this aggressive and rare form of non-Hodgkin lymphoma.

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Randomized clinical trials still showed that microbiota restoration is significantly more effective than antibiotics for recurrent Clostridioides difficile infection.

There are 8 million cancer survivors who may have limitations in their daily functional ability.

People with less severe symptoms of insomnia still had a 16% increased risk of stroke compared to people with no symptoms.

There may be more than 200 symptoms associated with long COVID-19.

Levels of troponin were higher in people who had type 2 diabetes for a longer period than people with healthy blood levels.

Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.

Asking patients to “give us a month of [their] life” for autologous chimeric antigen receptor therapy may reduce relapse or recurrence for 4 years or more, according to expert.

In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.

Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.

When physicians followed up, rates of screening improved for breast and cervical cancer by 50% and 250%, respectively, among eligible cancer survivors.

Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.

Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.

Identifying alterations in tumor genes has enabled medical oncologists to guide patients towards more specific therapies.

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

The 2023 ASCO Annual Meeting is being held in Chicago, Illinois from June 2 to 6.

Former and current smokers showed higher mortality from early-stage non-small cell lung cancer than never smokers.

Products include an antidepressant and treatment for hypertension.

The radiohybrid imaging agent allowed positron emission tomography to identify prostate cancer with an 83% detection rate.

Repotrectinib is a promising next-generation tyrosine kinase inhibitor under investigation for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer.

Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.

Untreated hearing loss can affect communication, loneliness, and lead to severe illness, such as dementia.

In Greece, the stark increase in Clostridioides difficile (C. diff) incidence cannot be explained by a rise of antimicrobial use during the pandemic.

Bictegravir/emtricitabine/ tenofovir alafenamide tablets (B/F/TAF) provides long-term virologic suppression for nearly 100% of patients.

This is the first clinical evidence to show that stimulating the programmed cell death protein 1 (PD1) inhibitory pathway is beneficial for rheumatologic disease.

The steroid could be more effective for veterans with post-traumatic stress disorder who do not have a history of traumatic brain injury.